ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval

Sep 28, 10:00 AM
Headliner
Share
Subscribe
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Share
Subscribe
Next
ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy
Top episodes
AI in Clinical Trials - A Long, But Promising Road Ahead
by Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
by Applied Clinical Trials
Diversity in Clinical Trials: The Need to Take Action
by Applied Clinical Trials